Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
51 hedge funds and large institutions have $483M invested in Fusion Pharmaceuticals Inc. Common Shares in 2020 Q2 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
+$63.9M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$61M |
| 3 |
O
OrbiMed
New York
|
+$56.2M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$54.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.9M |
Top Sellers
FUSN Hedge Fund Activity: Q2 2020 in Review
51 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2020, worth a combined $483M.
Buyers outnumbered sellers: 51 funds opened new FUSN positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Johnson & Johnson Innovation - JJDC, opening a new position worth an estimated $63.9M.
- 51 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $483M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2020.
- 51 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2020 and 0 closed out, a net change of +51 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2020 was Johnson & Johnson Innovation - JJDC, an estimated $63.9M added.
Based on aggregated 13F filings for Q2 2020.